Showing results (31-40 of 55) with videos related to
Sort By:
Pageof 6
Biorxiv : the Preprint Server for Biology|August 13, 2025
Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticityLetian Zhang, Meenalakshmi Chinnam, Bradley Balk, et al.Science Translational Medicine|March 30, 2022
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cellsMoiez Ali, Min Lu, Hazel Xiaohui Ang, et al.Journal of the American Geriatrics Society|October 6, 2021
Changes in older adults' life space during lung cancer treatment: A mixed methods cohort studyMelisa L Wong, Ying Shi, Alexander K Smith, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2023
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or ChemotherapyKai He, David Berz, Shirish M Gadgeel, et al.Cell Reports|April 7, 2015
NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerCollin M Blakely, Evangelos Pazarentzos, Victor Olivas, et al.JTO Clinical and Research Reports|September 30, 2021
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized StudyJames Chih-Hsin Yang, Karen L Reckamp, Young-Chul Kim, et al.Nature Cancer|April 18, 2024
PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumorsSanju Sinha, Rahulsimham Vegesna, Sumit Mukherjee, et al.Nature Cell Biology|August 15, 2018
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancersRobert J Nichols, Franziska Haderk, Carlos Stahlhut, et al.Nature Medicine|November 28, 2018
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancerKhyati N Shah, Roma Bhatt, Julia Rotow, et al.Nature Medicine|August 25, 2015
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancerGorjan Hrustanovic, Victor Olivas, Evangelos Pazarentzos, et al.Pageof 6